-
Recent Posts
Archives
- April 2020
- December 2018
- August 2018
- June 2018
- March 2018
- November 2017
- September 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- September 2015
- August 2015
- July 2015
- June 2015
- April 2015
- March 2015
- February 2015
- January 2015
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
Blog Categories
Category Archives: cancer
Novel PEG hydrogel as 3D synthetic extracellular matrix (ECM) for organoid culture
A recent article published in the leading scientific journal of Nature (Designer matrices for intestinal stem cell and organoid culture, Matthias P. Lutolf et al from the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland, Nature, Published online 16 November 2016, … Continue reading
Posted in Blogs, cancer, Regenerative medicine
1 Comment
PEGfilgrastim (Neulasta) Approved for Treatment of Acute Radiation Syndrome
In November 2015, the Food and Drug Administration approved the use of Amgen’s pegfilgrastim (Neulasta) to increase survival of people acutely exposed to high-dose radiation that damages the bone marrow, which will improve access to the drug in the event … Continue reading
Posted in Biologic, Blogs, cancer, chemotherapy
Leave a comment
The next stop for PEGylated protein drugs: Biosimilar
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor analog filgrastim. It serves to stimulate the level of white blood cells. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim … Continue reading
Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation
Leave a comment
Can a PEGylated protein be ever considered a Biosimilar drug?
In March 2015, the FDA approved the first biosimilar drug for use in the United States. The drug called Zarxio, produced by Sandoz, is used to help prevent infections in cancer patients receiving chemotherapy, and it is a biosimilar alternative … Continue reading
Posted in Biologic, Biosimilar, Blogs, cancer, chemotherapy, pegylation, PEGylation Reagents
Tagged biologic, biosimilar, Cancer, chemotherapy, PEGylation, pegylation reagents, protein pegylation
Leave a comment